Physician profile
Ryan C Beck
NPI 1649654369
$46,546.07
in general payments reported to CMS, 2019-2025
19 companies · $14K in 2025
The $14K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,127 · 2020: $547 · 2021: $803 · 2022: $3,244 · 2023: $8,938 · 2024: $18K · 2025: $14K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,516 · Consulting Fee: $6,000 · Food and Beverage: $5,693 · Travel and Lodging: $5,614 · Education: $2.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $17,000.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,516.30 |
| Consulting Fee | $6,000.00 |
| Food and Beverage | $5,693.14 |
| Travel and Lodging | $5,613.54 |
| Education | $2.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $24,744.15 | 2022-2025 | Miebo, Xiidra, Infuse |
| Johnson & Johnson Surgical Vision, INC. | $15,586.09 | 2020-2024 | Lipiflow System Activator (Disposable), Meibomian Gland Evaluator |
| Johnson & Johnson Vision Care, INC. | $2,849.66 | 2019-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $973.96 | 2019-2021 | |
| Oyster Point Pharma, INC. | $466.79 | 2022-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Alcon Vision LLC | $410.92 | 2019-2025 | Total30, Eysuvis, Rocklatan |
| Novartis Pharmaceuticals Corporation | $288.08 | 2020-2023 | |
| Dompe US, INC. | $270.95 | 2022-2025 | Oxervate |
| Sun Pharmaceutical Industries INC. | $205.02 | 2020-2024 | Cequa |
| Sight Sciences, INC. | $173.12 | 2023 | Tearcare System |
| Glaukos Corporation | $148.63 | 2025 | Photrexa Viscous and Photrexa |
| Quidel Corporation | $132.65 | 2020-2022 | |
| Harrow Eye, LLC | $98.92 | 2025 | Vevye |
| Optos, INC. | $98.51 | 2020 | |
| Tarsus Pharmaceuticals, INC. | $22.75 | 2024 | Xdemvy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $22.19 | 2021 | |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Carl Zeiss Meditec, INC. | $17.24 | 2020 | |
| Integra Lifesciences Corporation | $17.04 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.